CliffBio
small molecule

LOTEPREDNOL ETABONATE AND TOBRAMYCIN

LOTEPREDNOL ETABONATE; TOBRAMYCIN

Loss of exclusivityJuly 2026FDA regulatory exclusivity expiry
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameLOTEPREDNOL ETABONATE AND TOBRAMYCIN
Active ingredientLOTEPREDNOL ETABONATE; TOBRAMYCIN
Strength0.5%;0.3%
Dosage formSUSPENSION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalDecember 2025
Marketing statusRX

Regulatory exclusivity

CodeExpires
CGTJuly 2026

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.